ADAC mum on new product news
Nuclear medicine vendor ADAC Laboratories (Hall B, #6711) is promising a new product announcement for the meeting but is planning to keep the news to itself until the show. One new product the Milpitas, CA-based company is talking about is WebView, a
Nuclear medicine vendor ADAC Laboratories (Hall B, #6711) is promising a new product announcement for the meeting but is planning to keep the news to itself until the show. One new product the Milpitas, CA-based company is talking about is WebView, a work-in-progress workstation that enables physicians to interpret and process images in their departments, homes, or offices.
General-purpose and specialized SPECT and cardiac displays have been built into WebView. In addition to nuclear medicine studies, WebView supports multimodality images via the DICOM 3.0 standard. The software runs on Windows NT and Windows 95 operating systems.
ADAC will also discuss MCD/AC, the company's high-energy Molecular Coincidence Detection upgrade package with attenuation correction capabilities. MCD/AC uses an external cesium-137 radioactive source to create an attenuation map of tissue densities in the body, and this map is used to compensate for artifacts created by tissue, bone, and other obstructions (SCAN 6/25/97).
MCD/AC improves the visualization of organs and structures deep in the body and could help extend coincidence detection from oncology applications into cardiology uses. MCD/AC received 510(k) clearance in October.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
